购物车
  • 全部删除
  • TargetMol
    您的购物车当前为空

Fedratinib

产品编号 T1995Cas号 936091-26-8
别名 TG-101348, SAR 302503

Fedratinib (TG-101348) 是一种 JAK2 抑制剂,具有选择性、ATP 竞争性和具有口服活性,抑制 JAK2 和 JAK2V617F 激酶 (IC50=3 nM)。Fedratinib 可诱导肿瘤细胞凋亡,并可用于骨髓增生性疾病的研究。

Fedratinib

Fedratinib

纯度: 99.96%
产品编号 T1995 别名 TG-101348, SAR 302503Cas号 936091-26-8

Fedratinib (TG-101348) 是一种 JAK2 抑制剂,具有选择性、ATP 竞争性和具有口服活性,抑制 JAK2 和 JAK2V617F 激酶 (IC50=3 nM)。Fedratinib 可诱导肿瘤细胞凋亡,并可用于骨髓增生性疾病的研究。

规格价格库存数量
2 mg¥ 265现货
5 mg¥ 379现货
10 mg¥ 543现货
25 mg¥ 773现货
100 mg¥ 1,198现货
200 mg¥ 1,995现货
500 mg¥ 4,280现货
1 mL x 10 mM (in DMSO)¥ 481现货
大包装 & 定制
加入购物车
实验操作小课堂
查看更多

"Fedratinib"的相关化合物库

选择批次:
纯度:99.96%
联系我们获取更多批次信息
TargetMol 的所有产品仅用作科学研究或药证申报,不能被用于人体,我们不向个人提供产品和服务。请您遵守承诺用途,不得违反法律法规规定用于任何其他用途。

产品介绍

生物活性
产品描述
Fedratinib (TG-101348) is a JAK2 inhibitor that is selective, ATP-competitive, and orally active, inhibiting JAK2 and JAK2V617F kinases (IC50=3 nM). Fedratinib induces apoptosis in tumor cells and may be used in myeloproliferative diseases.
靶点活性
JAK2 (V617F):3 nM (cell free), JAK2:3 nM (cell free), RET:48 nM (cell free), FLT3:15 nM (cell free)
体外活性
方法:人成红细胞白血病细胞 HEL 和 Ba/F3 JAK2V617F 细胞用 Fedratinib (0-30 µM) 处理 72 h,使用 XTT assay 检测细胞增殖。
结果:Fedratinib 抑制了携带 JAK2V617F 突变的 HEL 细胞系以及表达人 JAK2V617F (Ba/F3 JAK2V617F) 的鼠前 B 细胞系的增殖,两种细胞系的 IC50 值分别为 305 nM 和 270 nM。[1]
方法:人骨髓间充质干细胞 hMSC-TERT 用 Fedratinib (3 µM) 处理 10 天,进行碱性磷酸酶 (ALP) 染色检测成骨分化。
结果:Fedratinib 处理的 hMSC-TERT 细胞表现出 ALP 产生的显著减少。与对照细胞相比,成骨细胞分化诱导后第 10 天的 ALP 活性测量值降低。Fedratinib 对 hMSC-TERT 细胞的活力没有产生显著影响。[2]
体内活性
方法:为研究对已建立的真性红细胞增多症的疗效,将 Fedratinib (60-120 mg/kg) 灌胃给药给 C57BL/6 小鼠骨髓移植模型,每天两次,持续 42 天。
结果:在接受治疗的动物中,红细胞压积和白细胞计数在统计学上显著降低,髓外造血的减少/消除呈剂量依赖性,至少在某些情况下,有证据表明骨髓纤维化减轻。[1]
激酶实验
IC50 values for TG101348 are determined commercially using the InVitrogen kinase profiling service for a 223 kinase screen that included JAK2 and JAK2V617F or Carna Biosciences for the screen of all Janus kinase family members including JAK1 and Tyk2. ATP concentration is set to approximately the Km value for each kinase [1].
细胞实验
Cells were treated with DMSO and increasing concentrations of inhibitor for 4 hr in RPMI-1640 before collected in 13 Cell Lysis Buffer, containing 1 mM PMSF, and protease inhibitor cocktail tablets. Protein lysates were quantified with BCA assay. Similar protein amounts were mixed with Laemmli sample buffer plus b-mercaptoethanol, boiled for 5 min, and separated on a 4%–15% Tris-HCl gradient electrophoresis gel. Gels were blotted onto a 0.45 mm nitrocellulose membrane, which was blocked in 5% nonfat dry milk and incubated with primary antibodies in either blocking solution or 5% BSA. The membranes were subsequently incubated with a mixture of donkey anti-rabbit IgG conjugated with infrared fluorophore (700 nm emission) and goat anti-mouse IgG conjugated with infrared fluorophore (800 nm emission). Following washing with PBS, the membranes were scanned on an Odyssey scanner to detect total (red) and phospho-STAT5 (green) proteins [1].
动物实验
The murine BM transplant model was generated and analyzed exactly as previously described. Briefly, C57BL/6 mice were intravenously injected with 1×10^6 whole bone marrow expressing JAK2V617F. Full development of disease was assessed with differential peripheral blood counts at day 26 after bone marrow transplantation. TG101348 was administered by oral gavage twice daily (b.i.d.) at 60 mg/kg, 120 mg/kg, or placebo from day 28 on for 42 days. Differential blood counts were assessed by retro-orbital nonlethal eye bleeds using EDTA glass capillary tubes before study initiation, during the study, and at study endpoints. C57/Bl6 mice were sacrificed at study endpoint or at times indicated based on an IUCAC-approved protocol that includes assessment of morbidity by > 10% loss of weight, scruffy appearance, lethargy, and/or splenomegaly extending across the midline. For histopathology, tissues were fixed in 10% neutral buffered formalin, embedded in paraffin, and stained with hematoxylin and eosin or, to assess for fibrosis, stained with reticulin. Images of histological slides were obtained on a Nikon Eclipse E400 microscope equipped with a SPOT RT color digital camera model 2.1.1. Images were analyzed in Adobe Photoshop 6.0. For flow cytometry, cells were washed in PBS, washed in 2% fetal bovine serum, blocked with Fc-Block for 10 min on ice, and stained with monoclonal antibodies in PBS and 2% FCS for 30 min on ice. Antibodies used were allophycocyanin (APC)-conjugated ter119, Gr-1, CD4, and B220 and phycoerythrin (PE)-conjugated, Mac1, CD8 (all 1:200), and CD71(1:100) rat anti-mouse. After washing, cells were resuspended in PBS and 2% FCS containing 0.5 mg/ml 7-amino-actinomycin D (7-AAD) to allow discrimination of nonviable cells. Flow cytometry was performed on a FACS Calibur cytometer, at least 10,000 events were acquired, and data were analyzed using FloJo software.The results are presented as graphs and representative dot plots of viable cells selected on the basis of scatter and 7-AAD staining [1].
别名TG-101348, SAR 302503
化学信息
分子量524.68
分子式C27H36N6O3S
CAS No.936091-26-8
储存&溶解度
存储Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.
溶解度信息
10% DMSO+40% PEG300+5% Tween 80+45% Saline: 9.3 mg/mL (17.73 mM), Please add co-solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately.
DMSO: 50 mg/mL (95.3 mM)
H2O: < 1 mg/mL (insoluble or slightly soluble)
Ethanol: < 1 mg/mL (insoluble or slightly soluble)
溶液配制表
10% DMSO+40% PEG300+5% Tween 80+45% Saline/DMSO
1mg5mg10mg50mg
1 mM1.9059 mL9.5296 mL19.0592 mL95.2962 mL
5 mM0.3812 mL1.9059 mL3.8118 mL19.0592 mL
10 mM0.1906 mL0.9530 mL1.9059 mL9.5296 mL
DMSO
1mg5mg10mg50mg
20 mM0.0953 mL0.4765 mL0.9530 mL4.7648 mL
50 mM0.0381 mL0.1906 mL0.3812 mL1.9059 mL

计算器

  • 摩尔浓度 计算器
  • 稀释 计算器
  • 配液 计算器
  • 分子量 计算器

体内实验配液计算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:
TargetMol | Animal experiments比如您的给药剂量是 10 mg/kg ,每只动物体重 20 g ,给药体积 100 μLTargetMol | Animal experiments 一共给药动物 10 只 ,您使用的配方为 5% TargetMol | reagent DMSO+ 30%PEG300+ 5%Tween 80 + 60% ddH2O. 那么您的工作液浓度为 2 mg/mL
母液配置方法: 2 mg 药物溶于 50 μLDMSOTargetMol | reagent ( 母液浓度为 40 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:50μLDMSOTargetMol | reagent 母液,添加 300 μLPEG300TargetMol | reagent 混匀澄清,再加 50μLTween 80, 混匀澄清,再加 600μLddH2OTargetMol | reagent 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

1 请输入动物实验的基本信息
mg/kg
g
μL
2 请输入动物体内配方组成,不同的产品配方组成不同,如有配方需求,可先联系我们提供正确的体内配方。
% DMSO
%
%Tween 80
%ddH2O

剂量转换

对于不同动物的给药剂量换算,您也可以参考 更多

关键词

Related Tags: buy Fedratinib | purchase Fedratinib | Fedratinib cost | order Fedratinib | Fedratinib chemical structure | Fedratinib in vivo | Fedratinib in vitro | Fedratinib formula | Fedratinib molecular weight